UNSPSC 51262204: Piperoxan hydrochloride

This classification denotes an alpha-adrenergic blocking agent with the molecular formula C14H19NO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KS0DZ1UQNW, chemically known as 1,4-benzodioxan, 2-(1-piperidylmethyl)-, hydrochloride but more generally known as piperoxan hydrochloride, which bears US NIH Compound Identifier 101619. Most nations, for tariff and trade purposes, schedule piperoxan hydrochloride under HS 29349990 and SITC 51579. As of Q4 2014, PIPEROXAN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity.

Piperoxan hydrochloride bears US NLM identifiers UMLS ID C2825596 and NCI Concept Code C81370. SMILES: C1CCC2C(C1)OCC(O2)CN3CCCCC3.CL.

UNSPSC 51262204 Piperoxan hydrochloride is a Commodity code for a specific pharmaceutical compound, but state and local procurement activity tagged under this code shows a significant mismatch with its nominal scope. The single recent opportunity in the dataset—Seminole County, Florida's IFB for naloxone and drug deactivation systems—does not involve piperoxan hydrochloride and instead reflects community health procurement for opioid-overdose response products and related equipment. The code shows little relevant recent activity aligned with its pharmaceutical designation.

Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding, with quarterly deliveries to the Seminole County Community Health Building at 520 W. Lake Mary Blvd, Sanford, Florida. The initial contract term is two years with a one-year renewal option. Vendors must include all shipping and delivery costs in their proposals, comply with drug-free workplace certification and E-Verify requirements, maintain workers' compensation and commercial general liability insurance, and navigate potential FEMA funding compliance including Clean Air Act and Federal Water Pollution Control Act adherence. The procurement uses a fixed-fee model and includes a three-month probationary period allowing termination with or without cause. The mismatch between the code's pharmaceutical scope and the actual goods being procured suggests either a tagging error in the source data or that this UNSPSC category does not represent active state and local demand for piperoxan hydrochloride specifically.